Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer

Fineline Cube Mar 14, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...

Company Drug

CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing

Fineline Cube Mar 14, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...

Deals R&D

Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences

Fineline Cube Mar 14, 2023

France’s Pasteur Institute has announced its decision to suspend its joint-venture (JV) partnership with the...

Company Medical Device

Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China

Fineline Cube Mar 14, 2023

US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...

Company Drug

Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan

Fineline Cube Mar 13, 2023

Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...

Company Deals

Silicon Valley Bank Collapse Impacts Tech and Biotech Sectors Globally

Fineline Cube Mar 13, 2023

The tech and biotech sectors are grappling with the implications of the collapse of US-based...

Company Deals

Allorion Therapeutics Raises USD 50 Million in Series B Financing to Advance Drug Development

Fineline Cube Mar 13, 2023

Allorion Therapeutics, a next-generation precision medicine small molecule drug developer based in Guangzhou, reportedly raised...

Company Deals

XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development

Fineline Cube Mar 13, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has partnered with China’s Chia Tai Tianqing to...

Company Deals

Overland Pharmaceuticals Partners with GoBroad Healthcare to Strengthen Cell Therapy Research

Fineline Cube Mar 13, 2023

China-based firm Overland Pharmaceuticals has entered into a strategic partnership with GoBroad Healthcare Group to...

Company Drug

Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806

Fineline Cube Mar 13, 2023

Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...

Company Drug

CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine

Fineline Cube Mar 13, 2023

China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...

Company Deals

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Fineline Cube Mar 13, 2023

China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100...

Company Deals

Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan

Fineline Cube Mar 13, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with South Korean...

Company Drug

CStone’s Ayvakit Shows Significant Improvements in ISM at AAAAI Meeting

Fineline Cube Mar 13, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that its US partner, Blueprint Medicines, published detailed data...

Company Medical Device

Lifetech’s IBS Angel Stent System Gains EU CE MDR Certification

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Secures Funding for Manufacturing Expansion in Pre-Series A+ Round

Fineline Cube Mar 10, 2023

Olipharma, a Contract Development and Manufacturing Organization (CDMO) specializing in small nucleic acid drugs and...

Company Drug

Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...

Company Drug

Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Posts pagination

1 … 595 596 597 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.